Weekly Investment Analysts’ Ratings Changes for OncoCyte (OCX)

OncoCyte (NASDAQ: OCX) recently received a number of ratings updates from brokerages and research firms:

• 9/27/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/28/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/22/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/16/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/10/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/9/2024 – OncoCyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.25 price target on the stock.
• 8/4/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

OncoCyte Stock Performance

Shares of NASDAQ OCX traded down $0.05 during midday trading on Monday, reaching $2.83. 4,407 shares of the company were exchanged, compared to its average volume of 37,091. OncoCyte Co. has a 1 year low of $2.08 and a 1 year high of $4.34. The stock has a fifty day simple moving average of $3.11 and a 200 day simple moving average of $2.93.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.